SMSbiotech Advances to First-in-Human Phase 1 Clinical Trial for COPD with Innovative Stem Cell Therapy San Diego-based regenerative medicine company begins groundbreaking trial in Australia, aiming to restore lung function in millions of patients worldwide. SMSbiotech, a biotechnology company headquartered…
Savara’s Landmark IMPALA-2 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis to Be Published in The New England Journal of Medicine Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to advancing therapies for rare respiratory diseases,…
Develop Health Raises $14.3 Million Series A to Automate Prior Authorization and Medication Access with Generative AI Develop Health, a fast-growing healthcare technology company focused on modernizing benefits verification and prior authorization, announced today that it has raised $14.3 million…
Scipher Medicine Launches ClinicalTrialRank.com: AI-Powered Platform to Predict Clinical Trial Failure and Transform Drug Development Strategy Scipher Medicine, a pioneering company in precision immunology and network medicine, has officially announced the public launch of ClinicalTrialRank.com, a first-of-its-kind artificial intelligence (AI)…
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a diverse pipeline of genetic therapies for rare and devastating disorders,…
MedImpact Unveils Affordable Access to Unbranded Ustekinumab-aekn Biosimilar, Reshaping Specialty Pharmacy Market MedImpact Holdings Inc., the nation’s largest independent pharmacy benefit and healthcare solutions provider, announced a major step toward addressing escalating specialty drug costs with the launch of access…
jCyte Marks Major Milestone with First Patients Treated in JC02-88 Clinical Trial Evaluating jCell for Retinitis Pigmentosa jCyte, Inc., a clinical-stage biotechnology company pioneering cell-based therapies for retinal diseases, announced a pivotal advancement in its development program: the enrollment and…
RenovoRx Reports Strong Q2 2025 Revenue Growth and Receives Positive Independent Committee Recommendation to Continue Phase III TIGeR-PaC Trial RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage life sciences company pioneering targeted oncology drug delivery therapies, announced financial results for the second…
ScaleReady Awards $300,000 G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory to Advance Modular CAR T-Cell Manufacturing ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, today announced that the Translational Sciences Laboratory at the Gates…
Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…
Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies for difficult-to-treat liver and gastrointestinal cancers, announced today a new…
Response Pharmaceuticals Announces Positive Phase 2 Results for RDX-002 in Post-GLP-1 Obesity Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation therapies for weight management and metabolic health, has reported encouraging top-line results from a double-blind, placebo-controlled…